Clinical and serological rebounds in infants with congenital toxoplasmosis: Follow-up during the first 2 years of life;Etude des poussees cliniques evolutives et des rebonds serologiques d'enfants atteints de toxoplasmose congenitale et suivis durant les 2 premieres annees de vie

Archives de Pediatrie

Volumn 4, Issue 10, 1997, Pages 940-946

  Fortier, B ^a,b   Coignard Chatain, C ^a   Dao, A ^a   Rouland, V ^c   Valat, A S ^a   Vinatier, D ^a   Lebrun, T ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Service de médecine nucléaire HÔpital Huriez   (France)

^d Ctr Rech Economiques S   (France)

Author keywords

Congenital toxoplasmosis; Follow up studies; Immunologic surveillance; Treatments

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PYRIMETHAMINE; SPIRAMYCIN; SULFONAMIDE; IMMUNOGLOBULIN M;

ANTIBODY DETECTION; ARTICLE; CONGENITAL TOXOPLASMOSIS; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; IMMUNOSURVEILLANCE; INFANT; MAJOR CLINICAL STUDY; MALE; SEROLOGY; TOXOPLASMA GONDII; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRESCHOOL CHILD; TOXOPLASMOSIS;

CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC SURVEILLANCE; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL;

EID: 0031241530     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(97)86088-5     Document Type: Article

References (20)

1. Fortier B, Coignard-Chatain C, Soete M, Dubremetz JF. Structure et biologie des bradyzoïtes de Toxoplasma gondii. C R Séances Soc Biol Fil 1996;190:385-94
2. Koppe JG, Kloosterman GJ, de Roever-Bonnet H et al. Toxoplasmosis and pregnancy, with a long-term follow up of the children. Eur J Obstet Gynaecol Reprod Biol 1974;4: 101-9
3. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980;66: 767-74
4. Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986;i:254-5
5. Coignard-Chatain C, Fortier B, Labalette P. Apport de la PCR dans le diagnostic biologique des toxoplasmoses oculaires actives. Méd Mal Infect 1996;26:529-33
6. Peyron F, Wallon M, Bernardoux C. Long-term follow-up of partients with congenital ocular toxoplasmosis. N Engl J Med 1996;334:993-4
7. Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol 1989;27:1787-92
8. Coignard-Chatain C, Fortier B, Gheron B et al. Intérêt du diagnostic précoce de la toxoplasmose congénitale. Bul Soc Fr Parasitol 1995;13:17-27
9. Desmonts G, Daffos F, Forestier F, Capella-Pavlovsky M, Thulliez P, Chartier M. Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985;i:500-4
10. Pinon JM, Chemla C, Villena I et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. J Clin Microbiol 1996;34:579-83
11. Garin JP, Mojon M, Piens MA, Chevallier-Nuttall I. Surveillance et traitement de la toxoplasmose chez la femme enceinte, le fœtus et le nouveau-né. Pédiatrie 1989;44:705-12
12. Piens MA, Garin JP. New perspectives in the chemoprophylaxis of toxoplasmosis. J Chemother 1989;1:46-51
13. Couvreur J, Thulliez P, Daffos F et al. In utero treatment of toxoplasmosis foetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther 1993;8:45-50
14. Maisonneuve H, Faber C, Piens MA, Garin JP. Toxoplasmose congénitale, tolérance de l'association sulfadoxine-pyriméthamine. 24 observations. Presse Méd 1984;13: 859-62
15. Couvreur J, Desmonts G. Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Dev Med Child Neural 1962;4:519-25
16. Goyal M, Ganguly NK, Mahajan RC. Immunological response in experimentally reactivated toxoplasmosis in mice. Med Microbiol Immunol 1989;178:269-78
17. Filice GA. The immunologie paralysis of congenital infection. J Lab Clin Med 1990;116:610-2
18. Leport C, Vilde JL, Katlama C, Régnier B, Matheron S, Saimot AG. Failure of spiramycin to prevent neurotoxoplasmosis in immunosuppressed patients. JAMA 1986;255: 2290
19. McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72
20. Georgiev VS. Management of toxoplasmosis. Drugs 1994; 48:179-88